Q&A Project Optimus: What you need to know

The study designs and dose-finding strategies that have dominated decades of oncology drug development are becoming obsolete as the FDA’s Project Optimus takes full effect. We rounded up our regulatory experts and asked them to share their perspectives on 28 of the top questions from sponsors.

Open PDF

Return to Insights Center

Related Insights


New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022


Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022


The clock is ticking on EU-CTR transitions: To meet the deadline, act now

May 20, 2024


New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022


Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022


RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022


Parexel names first Patient Ambassador

Jun 17, 2022


8 things you need to know about eCTDs in China

Jul 1, 2022


Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022


EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022


Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022


U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?

Aug 17, 2022